Tornar a Working Papers

Paper #1322

Launching prices for new pharmaceuticals in heavily regulated and subsidized markets
Jaume Puig i Beatriz González López-Valcárcel
Maig 2012
This paper provides empirical evidence on the explanatory factors affecting introductory prices of new pharmaceuticals in a heavily regulated and highly subsidized market. We collect a data set consisting of all new chemical entities launched in Spain between 1997 and 2005, and model launching prices. We found that, unlike in the US and Sweden, therapeutically "innovative" products are not overpriced relative to "imitative" ones. Price setting is mainly used as a mechanism to adjust for inflation independently of the degree of innovation. The drugs that enter through the centralized EMA approval procedure are overpriced, which may be a consequence of market globalization and international price setting.
Paraules clau:
pharmaceuticals; price competition; price regulation
Codis JEL:
L11, L65, I10, I18
Àrea de Recerca:
Economia Laboral, Pública, de Desenvolupament i de la Salut

Descarregar el paper en format PDF (7.448 Kb)

Cercar Working Papers

Per data:
-cal seleccionar un valor a les quatre llistes desplegables-

Consultes Predefinides